If you or someone you know has taken Reglan and is experiencing involuntary movements, you may be concerned about the long-term outlook. Recent studies continue to shed light on the risks and progression of tardive dyskinesia associated with this medication. Building on decades of pharmacovigilance data, this page summarizes current research findings and what they mean for patients and healthcare providers.
Reglan (metoclopramide) is a prescription medication approved for short-term use in adults with symptomatic gastroesophageal reflux or diabetic gastroparesis. However, its association with tardive dyskinesia (TD), a potentially irreversible movement disorder, has led to significant litigation. In New Jersey, patients harmed by Reglan must be aware of the statute of limitations, which governs the time frame for filing a lawsuit. This section examines the medical evidence linking Reglan to TD, the adequacy of warnings, and settlement considerations, grounded in the provided evidence. Tardive dyskinesia is a neurological syndrome characterized by involuntary, repetitive movements of the face, tongue, trunk, or extremities. Clinical presentation often includes grimacing, lip smacking, tongue protrusion, and rapid eye blinking. Diagnosis relies on clinical examination and history of exposure to dopamine-blocking agents, such as metoclopramide. The condition can be disfiguring and may persist even after drug discontinuation. The risk of developing TD increases with longer treatment duration and higher cumulative doses of metoclopramide (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD, and the drug should be used for the shortest duration necessary, with periodic reassessment of continued need (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
Reglan's pharmacology involves dopamine D2 receptor antagonism in the chemoreceptor trigger zone, which enhances gastric motility. However, chronic blockade of dopamine receptors in the basal ganglia is believed to cause supersensitivity, leading to TD. The mechanistic pathway is well-documented: prolonged exposure to metoclopramide alters dopamine receptor sensitivity, resulting in involuntary movements. The FDA-approved labeling explicitly warns that metoclopramide can cause TD, a potentially irreversible serious movement disorder, and that the risk increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with diabetic gastroparesis, the maximum recommended treatment duration is 12 weeks; if longer use is unavoidable, routine monitoring for TD signs is advised (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is not recommended for pediatric patients due to the risk of TD and other extrapyramidal symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
The adequacy of warnings regarding Reglan and TD is a central issue in litigation. The boxed warning, the strongest FDA-required warning, states that metoclopramide can cause TD and that the risk increases with treatment duration and cumulative dose (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). It also notes that Reglan may suppress or partially suppress signs of TD, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Despite these warnings, many patients were prescribed Reglan for extended periods, sometimes years, without adequate monitoring. The labeling limits use to 12 weeks for gastroesophageal reflux and advises against longer use for diabetic gastroparesis unless unavoidable (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Plaintiffs often argue that these warnings were insufficient to prevent harm, especially when physicians prescribed the drug off-label or for prolonged durations.
Settlement considerations for affected patients in New Jersey depend on several factors, including the statute of limitations. In New Jersey, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally two years from the date the injury was discovered or should have been discovered. For TD, this discovery date may be when symptoms first appeared or when a diagnosis was confirmed. The timeline between exposure to Reglan and documented harm is critical. TD can develop months or years after starting metoclopramide, and symptoms may persist or worsen even after discontinuation. The FDA warns that the risk of TD increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Therefore, patients who took Reglan for longer than 12 weeks may have a stronger claim, as this exceeds the recommended maximum duration. Settlement amounts in Reglan TD cases vary based on severity of symptoms, duration of exposure, and evidence of inadequate warnings. Many cases have been consolidated into multidistrict litigation, but individual state laws, including New Jersey's statute of limitations, apply. Patients must file within the two-year window from discovery of harm. Failure to do so may bar recovery. Legal counsel can help determine the exact filing deadline based on the patient's specific circumstances.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In New Jersey, the statute of limitations for personal injury claims, including those related to Reglan and tardive dyskinesia, is generally two years from the date the injury was discovered or should have been discovered. For TD, this discovery date may be when symptoms first appeared or when a diagnosis was confirmed. It is crucial to consult with an attorney to determine the exact deadline based on individual circumstances.
Reglan (metoclopramide) works by blocking dopamine D2 receptors in the brain. Chronic blockade of these receptors in the basal ganglia can lead to supersensitivity, resulting in involuntary movements characteristic of tardive dyskinesia. The risk increases with longer treatment duration and higher cumulative doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
The FDA requires a boxed warning for Reglan stating that metoclopramide can cause tardive dyskinesia, a potentially irreversible serious movement disorder. The warning emphasizes that the risk increases with duration of treatment and total cumulative dosage. Reglan should be used for the shortest duration necessary, and treatment beyond 12 weeks is not recommended for most conditions (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Individuals with documented Reglan exposure and a related diagnosis may request an independent, no-cost eligibility review.